<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820950</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-201</org_study_id>
    <nct_id>NCT00820950</nct_id>
  </id_info>
  <brief_title>A Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis</brief_title>
  <official_title>A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is comprised of two parts. The first portion of this study will be a double-blind,
      Sponsor-unblinded, vehicle-controlled study with application of INCB018424 or vehicle to
      paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part
      2 of the study is a double-blind, sponsor unblinded, comparison of INCB018424 with two FDA
      approved products in patients with active but stable plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of INCB018424, 0.5%, 1.0%, and 1.5% cream formulation applied once or twice daily compared with vehicle, Dovonex® calcipotriene 0.005% cream or Diprolene® AF betamethasone dipropionate 0.05% cream.</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4 and 8 (or early study termination visit)</time_frame>
    <description>Efficacy endpoints will include:
Efficacy Endpoint
Change in target lesion scores (erythema, E; scaling, S; and thickness, T) including total score (E+S+T) and each component analyzed separately.
Change in target lesion area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the safety of INCB018424 0.5%, 1.0% and 1.5% cream formulations when applied once or twice daily by monitoring the frequency, duration and severity of adverse and serious adverse events</measure>
    <time_frame>Baseline, Week 1, 2, 3, 4 and 8 (or early study termination visit). In addition, safety will also be assessed through the spontaneous reporting of serious adverse events</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Treatment 1: INCB018424</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB018424 -- 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2: INCB018424</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB018424 -- 1.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 3: INCB018424</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB018424 -- 1.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 5: Dovonex® calcipotriene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dovonex® calcipotriene 0.005% cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 6: Diprolene® AF betamethasone diproprionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB018424 phosphate cream</intervention_name>
    <description>INCB018424 phosphate cream 0.5%</description>
    <arm_group_label>Treatment 1: INCB018424</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dovonex® calcipotriene 0.005%</intervention_name>
    <description>Cream applied once or twice daily for up to 56 days.</description>
    <arm_group_label>Treatment 5: Dovonex® calcipotriene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprolene® AF betamethasone dipropionate 0.05% cream.</intervention_name>
    <description>Cream applied once or twice daily for up to 56 days</description>
    <arm_group_label>Treatment 6: Diprolene® AF betamethasone diproprionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo cream</intervention_name>
    <description>Cream applied once or twice daily for 56 days</description>
    <arm_group_label>Treatment 4: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB018424 phosphate cream</intervention_name>
    <description>INCB018424 phosphate cream 1.0%</description>
    <arm_group_label>Treatment 2: INCB018424</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB018424 phosphate cream</intervention_name>
    <description>INCB018424 phosphate cream 1.5%</description>
    <arm_group_label>Treatment 3: INCB018424</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of 17 to 40 kg/m2

          -  Subjects must have two comparable psoriatic lesions measuring between 9 and 100 cm2
             and these target lesions must be similar in size to each other, and separated by at
             least 15 cm.

        Exclusion Criteria:

          -  Subjects with lesions solely involving the palms of the hands or soles of the feet or
             intertriginous areas, the scalp or the face.

          -  Subjects with pustular psoriasis or erythroderma.

          -  Subjects currently on other topical agents or UVB therapy within 2 weeks of the first
             dose of study medication.

          -  Subjects receiving PUVA within 4 weeks of the first dose of study medication.

          -  Subjects receiving systemic retinoids, etanercept, adalimumab or efalizumab or oral
             immunosuppressives within 3 months prior to the first dose of study medication.

          -  Subjects receiving any other biological therapy (infliximab, alefacept, abatacept,
             etc) within 3 months of the first dose of study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Williams, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <disposition_first_submitted>June 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 22, 2010</disposition_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

